cbdMD (YCBD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jul, 2026Opening remarks and agenda
Meeting commenced virtually on March 30, 2026, with CEO/CFO Ronan Kennedy presiding and welcoming shareholders.
Attendees were informed about the agenda, conduct code, and procedures for submitting questions during the meeting.
Formal business was prioritized, with a plan to address additional questions after adjournment of the formal portion.
Board and executive committee updates
Directors and executive officers in attendance were introduced, including board members and the Chief Accounting Officer.
Brian Pearlman was appointed as Inspector of Elections for the meeting.
Corporate governance
Notice of meeting and proxy statement were distributed to shareholders of record as of February 2, 2026.
Proof of mailing and shareholder list procedures were confirmed and documented for transparency.
Quorum was established with over 33.3% of shares represented by proxy.
Latest events from cbdMD
- Revenue up 20% to $5.6M, cost cuts underway, break-even now at low to mid $6M quarterly.YCBD
Q3 2026 - Operating loss narrowed, liquidity improved, and regulatory shifts may drive major growth in 2026.YCBD
Q4 2025 - Revenue grew 19% to $5.6M, with Bluebird integration and Medicare channel shaping future growth.YCBD
Q2 2026 - Resale registration for 2M shares highlights dilution risk and growth from Bluebird acquisition.YCBD
Registration Filing - Q1 FY26 revenue rose 12% sequentially, with improved net loss and Bluebird acquisition boosting outlook.YCBD
Q1 2026 - Eight key proposals, including a reverse split and major share issuances, up for virtual vote.YCBD
Proxy Filing - Shareholders will vote on director elections, a reverse split, and major share issuances with dilution risk.YCBD
Proxy Filing - Net sales fell 10.9%–12% as Oasis expanded, margins held, and regulatory headwinds persisted.YCBD
Q3 2025 - Q2 FY25 saw higher sales, improved margins, and equity actions, but liquidity risks persist.YCBD
Q2 2025